FAPI-mFS

• Description:

  FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu[1]. FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

• UNSPSC:

  12352209

• Target:

  FAP; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fapi-mfs.html

• Purity:

  99.78

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C (N[C@H] (C (N1CCN (CCCOC2=CC=C (N=CC=C3C (NCC (N4[C@H] (C#N) CC (F) (F) C4) =O) =O) C3=C2) CC1) =O) CCCCNC (C5=CC (OS (F) (=O) =O) =CC=C5) =O) CN6CCN (CC (O) =O) CCN (CC (O) =O) CCN (CC (O) =O) CC6

• Molecular Formula:

  C53H69F3N12O15S

• Molecular Weight:

  1203.25

• References & Citations:

  [1]Cui XY, et al., Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024 Jun;630 (8015) :206-213.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  3023869-94-2